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Critically ill patients requiring acute renal replacement therapy are at an
increased risk of long-term renal dysfunction, but rarely receive specialist
nephrology follow-up.
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Critically	  ill	  patients	  requiring	  acute	  renal	  replacement	  therapy	  are	  at	  
increased	  risk	  of	  long-­‐term	  renal	  dysfunction,	  but	  rarely	  receive	  
specialist	  nephrology	  follow-­‐up.	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Background:	  Episodes	  of	  Acute	  Kidney	  Injury	  (AKI)	  have	  been	  associated	  with	  
development	  Chronic	  Kidney	  Disease	  (CKD).	  However,	  follow	  up	  pathways	  for	  
patients	  who	  have	  survived	  AKI	  complicating	  critical	  illness	  are	  not	  well	  established.	  
We	  hypothesized	  that	  patients	  who	  had	  AKI	  requiring	  renal	  replacement	  therapy	  
(RRT)	  in	  intensive	  care	  are	  at	  risk	  of	  CKD,	  but	  are	  rarely	  referred	  for	  nephrology	  
follow-­‐up	  at	  hospital	  discharge.	  	  
Methods:	  We	  performed	  a	  retrospective	  analysis	  of	  all	  patients	  who	  survived	  AKI	  
requiring	  renal	  replacement	  therapy	  in	  intensive	  care	  units	  (ICUs)	  in	  the	  East	  London	  
region,	  examining	  renal	  function	  at	  baseline,	  hospital	  discharge	  and	  3-­‐6	  months	  
follow-­‐up.	  We	  excluded	  patients	  who	  were	  known	  to	  renal	  services	  prior	  to	  index	  
admission.	  	  
Results:	  From	  5544	  critical	  care	  admissions	  we	  identified	  219	  patients	  who	  survived	  
to	  discharge	  having	  undergone	  RRT	  for	  AKI	  that	  were	  not	  previously	  known	  to	  renal	  
services.	  Of	  these,	  124	  (57%)	  had	  a	  creatinine	  measured	  within	  3-­‐6	  months	  after	  
discharge,	  104	  having	  a	  pre-­‐morbid	  baseline	  for	  comparison.	  Only	  26	  patients	  (12%)	  
received	  specialist	  nephrology	  follow-­‐up.	  At	  3-­‐6	  months	  follow-­‐up	  estimated	  
glomerular	  filtration	  rate	  was	  significantly	  lower	  than	  baseline	  (48	  vs.	  
60mLs/min/1.73m2	  p<0.001),	  with	  the	  prevalence	  of	  CKD	  stages	  III-­‐V	  rising	  from	  49%	  
to	  70%	  (p<0.001).	  	  
Conclusions:	  Follow-­‐up	  of	  patients	  who	  required	  RRT	  for	  AKI	  in	  ICU	  is	  inconsistent	  
despite,	  evidence	  of	  a	  significant	  increase	  in	  the	  prevalence	  of	  CKD.	  There	  is	  strong	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 3 
justification	  for	  development	  of	  robust	  pathways	  to	  identify	  survivors	  of	  AKI	  
following	  CKD	  and	  it	  complications	  to	  be	  detected	  and	  managed.	  
	  
Keywords	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Introduction	  
AKI	  is	  common	  and	  serious	  complication	  of	  critical	  illness	  [1]	  with	  a	  high	  
associated	  hospital	  mortality.[2]	  However,	  traditionally,	  recovery	  of	  pre-­‐morbid	  
renal	  function	  had	  been	  thought	  to	  occur	  in	  most	  of	  those	  who	  survive	  critical	  illness.	  
However,	  when	  accurate	  determinations	  are	  made,	  reductions	  in	  renal	  function	  can	  
be	  shown	  to	  persist	  long	  after	  the	  acute	  injury,	  consequently	  longer-­‐term	  outcomes	  
of	  patients	  who	  survive	  AKI	  are	  increasingly	  recognized	  as	  of	  key	  clinical	  
importance.[3]	  
	   Specialist	  management	  algorithms	  have	  been	  developed	  for	  follow	  up	  of	  
patients	  with	  recognized	  Chronic	  Kidney	  Disease	  (CKD),[4]	  however,	  follow-­‐up	  
pathways	  for	  patients	  who	  have	  suffered	  AKI	  complicating	  critical	  illness	  are	  not	  well	  
established.	  Importantly,	  the	  effects	  of	  prolonged	  major	  illness	  can	  confound	  serum	  
creatinine-­‐based	  assessment	  of	  CKD	  risk	  at	  hospital	  discharge.[5]	  To	  document	  
clinical	  need	  and	  current	  practice	  in	  our	  region	  we	  examined	  rates	  of	  specialist	  
follow-­‐up	  and	  development	  or	  progression	  of	  CKD	  in	  patients	  who	  received	  RRT	  in	  
the	  ICU	  over	  a	  one-­‐year	  period.	  
	  
	  




Design	  &	  data	  sources	  
This	  study	  was	  conducted	  as	  an	  institutionally	  approved	  service-­‐development	  audit	  
of	  outcomes	  and	  follow-­‐up	  of	  severe	  acute	  kidney	  injury	  against	  national	  
recommendations.[6]	  We	  performed	  a	  retrospective	  analysis	  of	  all	  adults	  in	  the	  East	  
London	  region	  (UK)	  requiring	  RRT	  following	  admission	  to	  ICU	  from	  1st	  January	  to	  31st	  
December	  2011.	  We	  excluded	  patients	  previously	  known	  to	  a	  nephrology	  specialist	  
with	  CKD,	  end	  stage	  renal	  disease	  or	  renal	  transplant	  prior	  to	  admission	  within	  the	  
last	  10	  years.	  	  
East	  London	  has	  a	  population	  of	  1.8	  million	  served	  by	  eight	  NHS	  hospitals	  (9	  
ICUs),	  supported	  by	  a	  central	  nephrology	  service.	  Seven	  ICUs	  are	  mixed	  medical-­‐
surgical,	  one	  serving	  a	  level-­‐1	  trauma	  center,	  while	  two	  are	  specialist	  cardio-­‐thoracic	  
units.	  In	  the	  UK,	  nephrologists	  are	  not	  routinely	  involved	  in	  the	  decision	  to	  
commence	  RRT,	  therefore	  in	  all	  the	  ICUs	  studied,	  RRT	  was	  initiated	  and	  managed	  
solely	  by	  the	  intensive	  care	  team	  using	  continuous	  veno-­‐veno	  haemofiltration	  or	  
haemodiafiltration.	  
	   Patient	  information	  was	  collated	  from	  ICNARC	  (Intensive	  Care	  National	  Audit	  
and	  Research	  Centre)	  ICU	  audit	  databases,	  central	  renal	  unit	  and	  local	  pathology	  
electronic	  records.	  We	  collected	  demographic	  data,	  baseline	  renal	  function	  (last	  
measurement,	  whether	  as	  a	  previous	  in-­‐patient	  or	  as	  an	  outpatient,	  before	  seven	  
days	  and	  up	  to	  one	  year	  prior	  to	  index	  hospital	  admission),	  hospital	  discharge	  
creatinine,	  details	  of	  follow-­‐up	  visits	  and	  creatinine	  measurements	  from	  3	  to	  6	  
months	  after	  hospital	  discharge.	  Estimated	  GFR	  (eGFR)	  was	  calculated	  using	  the	  CKD-­‐
EPI	  four-­‐variable	  creatinine	  equation.[7]	  Presumed	  cause	  of	  AKI	  was	  independently	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Analysis	  was	  performed	  using	  R:	  A	  language	  and	  environment	  for	  statistical	  
computing	  (http://www.R-­‐project.org).	  Continuous	  variables	  are	  reported	  as	  median	  
(range)	  and	  compared	  by	  Mann	  Whitney-­‐U	  or	  Wilcoxon	  signed	  rank	  tests,	  categorical	  
variables	  were	  compared	  using	  Fisher	  Exact	  or	  McNemar	  tests.	  	  Statistical	  
significance	  was	  defined	  by	  a	  two-­‐sided	  p	  value	  of	  <0.05.	  Simple	  linear	  regression	  
was	  used	  to	  investigate	  the	  relationship	  between	  discharge	  and	  follow-­‐up	  eGFR	  with	  
calculation	  of	  the	  coefficient	  of	  determination	  (Pearson	  r2).	  	  To	  assess	  whether	  
changes	  between	  repeated	  observations	  could	  be	  explained	  by	  regression	  to	  the	  
mean	  the	  regression	  line	  was	  compared	  against	  a	  predicted	  regression	  line,	  derived	  
from	  modeling	  repeated	  eGFR	  measurements	  using	  a	  high-­‐end	  estimate	  for	  the	  
coefficient	  of	  variation	  (CV)	  of	  20%.	  
	  
Results	  
There	  were	  5544	  ICU	  admissions	  in	  2011,	  781(14%)	  patients	  received	  renal	  
replacement	  therapy	  (RRT),	  of	  these	  261	  survived	  to	  hospital	  discharge	  and	  were	  not	  
known	  to	  renal	  services	  	  (Figure	  1).	  Distribution	  of	  cases	  between	  ICUs	  is	  shown	  in	  
Supplementary	  Table	  1.	  	  
Within	  three	  months	  of	  hospital	  discharge	  22	  died,	  seven	  commenced	  
maintenance	  renal	  replacement	  therapy,	  eight	  were	  re-­‐admitted	  to	  hospital	  and	  five	  
moved	  out	  of	  region	  (Figure	  1),	  leaving	  219	  patients	  where	  outpatient	  assessment	  of	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CKD	  status	  would	  be	  possible.	  	  182/219	  (83%)	  were	  offered	  a	  hospital	  follow-­‐up	  
appointment;	  142/182	  (78%)	  attended	  their	  appointment,	  but	  only	  78	  of	  those	  (55%	  
of	  those	  attending)	  had	  their	  creatinine	  measured	  at	  this	  visit.	  Twenty-­‐six	  patients	  
(12%)	  were	  reviewed	  in	  nephrology	  out-­‐patients	  and	  creatinine	  was	  checked	  in	  all	  of	  
these	  patients.	  Median	  time	  to	  first	  hospital	  appointment	  with	  any	  clinician	  was	  6	  
weeks	  (range	  1-­‐32).	  
	   Despite	  the	  low	  frequency	  of	  creatinine	  measurement	  at	  first	  outpatient	  visit,	  
124	  patients	  (57%)	  had	  a	  creatinine	  checked	  between	  3-­‐6	  months	  after	  hospital	  
discharge,	  either	  at	  another	  hospital	  visit	  or	  in	  primary	  care,	  providing	  results	  that	  
could	  be	  used	  for	  CKD	  assessment.	  The	  demographics	  of	  patients	  with	  and	  without	  
post-­‐discharge	  creatinine	  results	  are	  shown	  in	  Table	  1.	  Having	  a	  3-­‐6	  month	  
creatinine	  measurement	  was	  associated	  with	  lower	  pre-­‐morbid	  eGFR	  (60	  v	  67	  
ml/min/1.73m2;	  p=0.04)	  and	  a	  higher	  proportion	  of	  baseline	  CKD	  (53	  (51%)	  v	  38	  
(28%);	  p<0.001).	  	  Trauma	  was	  less	  frequent	  and	  obstruction	  more	  frequent	  in	  those	  
who	  had	  follow-­‐up	  creatinines.	  	  
There	  was	  no	  significant	  difference	  between	  creatinine	  measurements	  (121	  
(27-­‐617)	  vs.	  124	  (40-­‐645)µmol/L,	  p=0.13)	  or	  eGFR	  (46.5	  (5-­‐147)	  vs.	  49.5	  (2-­‐142)	  
ml/min/1.73m2;	  p=0.2)	  at	  hospital	  discharge	  compared	  to	  3-­‐6	  months	  later.	  
However,	  linear	  regression	  analysis	  between	  discharge	  and	  follow	  up	  eGFR	  
suggested	  significant	  variation	  in	  individual	  eGFR	  measurements	  during	  follow-­‐up	  
(r2=0.59).	  	  Overall,	  the	  regression	  equation	  suggested	  that	  eGFR	  values	  higher	  than	  
49ml/min/1.73m2	  tended	  to	  decrease	  during	  follow-­‐up,	  while	  values	  lower	  than	  this	  
tended	  to	  increase,	  this	  effect	  was	  larger	  than	  the	  predicted	  regression	  to	  the	  mean	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effect	  from	  repeated	  eGFR	  measurements,	  suggesting	  actual	  changes	  in	  eGFR	  were	  
occurring	  during	  the	  follow-­‐up	  period	  (Figure	  2).	  
In	  the	  sub-­‐group	  of	  104	  patients	  who	  had	  baseline,	  hospital	  discharge	  and	  
follow	  up	  creatinine	  measurements,	  baseline	  creatinine	  was	  significantly	  lower	  than	  
at	  hospital	  discharge	  creatinine	  and	  3-­‐6	  months	  later	  (99	  (51-­‐398)	  versus	  120	  (27-­‐
617)	  or	  126	  (40-­‐641)	  µmol/L	  respectively,	  p<0.0001	  for	  both).	  Similarly	  eGFR	  was	  
higher	  at	  baseline	  than	  at	  discharge	  or	  follow-­‐up	  	  (60	  (12-­‐141)	  v	  45	  (5-­‐142)	  and	  48	  (2-­‐
128)	  ml/min/1.73m2	  respectively,	  p<0.0001	  for	  both).	  Consequently,	  prevalence	  of	  
CKD	  III	  (eGFR	  <60)	  rose	  significantly	  from	  49%	  at	  baseline	  to	  70%	  at	  3-­‐6	  months	  
(Table	  2).	  	  There	  was	  a	  tendency	  for	  eGFR	  to	  decrease	  from	  baseline	  to	  follow-­‐up	  
across	  the	  whole	  range	  of	  baseline	  renal	  function,	  with	  a	  regression	  line	  lying	  
consistently	  below	  the	  line	  of	  identity	  (Figure	  3).	   	  
	  
Discussion	  
Summary	  of	  findings	  
We	  focused	  on	  a	  cohort	  of	  patients	  not	  previously	  known	  to	  renal	  services	  
surviving	  to	  hospital	  discharge	  after	  receiving	  RRT	  in	  ICU.	  As	  expected,	  there	  were	  
high	  rates	  of	  adverse	  outcomes	  after	  hospital	  discharge,	  14%	  dying,	  requiring	  
maintenance	  RRT	  or	  being	  re-­‐hospitalized	  within	  3	  months	  of	  hospital-­‐discharge.	  In	  
our	  cohort	  of	  patients	  developing	  RRT	  requiring	  AKI	  we	  observed	  a	  high	  prevalence	  
of	  pre-­‐morbid	  CKD	  (51%),	  in	  line	  with	  the	  well-­‐described	  role	  of	  CKD	  as	  the	  strongest	  
baseline	  risk	  factor	  for	  development	  of	  AKI.[3,8,9]	  
Of	  the	  219	  patients	  available	  for	  follow-­‐up	  only	  12%	  were	  referred	  to	  a	  
nephrologist.	  When	  seen	  by	  non-­‐nephrologists	  only	  55%	  had	  creatinine	  measured	  at	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their	  first	  follow-­‐up.	  When	  measured,	  the	  prevalence	  of	  CKD	  III,	  or	  greater,	  rose	  from	  
49	  to	  70%	  after	  critical	  illness	  and	  proportion	  with	  CKD	  IV	  or	  V	  more	  than	  doubled,	  
highlighting	  the	  importance	  of	  follow-­‐up	  for	  these	  patients.	  	  Falls	  in	  eGFR	  after	  
critical	  illness	  were	  seen	  at	  all	  levels	  of	  baseline	  function,	  but	  were	  unpredictable	  
between	  individuals	  (Fig.	  3)	  suggesting	  it	  may	  be	  difficult	  to	  prospectively	  select	  high	  
risk	  patients	  for	  progression	  of	  CKD	  at	  baseline.	  	  
We	  found	  no	  significant	  difference	  between	  eGFR	  at	  hospital	  discharge	  and	  
at	  3-­‐6	  months	  follow	  up.	  Both	  increases	  and	  decreases	  in	  eGFR	  can	  occur	  after	  
hospital	  discharge	  as	  a	  result	  of	  recovery,	  or	  further	  deterioration,	  in	  true	  GFR	  or	  
recovery	  of	  muscle	  mass.	  In	  the	  124	  patients	  with	  discharge	  and	  follow-­‐up	  eGFR	  the	  
coefficient	  of	  determination	  was	  0.59,	  implying	  that	  over	  40%	  of	  the	  variation	  in	  
follow-­‐up	  eGFR	  could	  not	  be	  accounted	  for	  by	  variation	  in	  discharge	  eGFR.	  Higher	  
eGFR	  values	  tended	  to	  decrease	  and	  lower	  values	  to	  increase	  (Fig.	  2),	  an	  effect	  that	  
was	  larger	  than	  could	  be	  accounted	  for	  by	  regression	  to	  the	  mean	  between	  repeated	  
measurements.	  Patients	  with	  lower	  eGFR	  at	  discharge	  may	  have	  more	  potential	  for	  
continued	  renal	  recovery,	  while	  increase	  in	  muscle	  mass	  may	  be	  more	  likely	  in	  those	  
with	  higher	  discharge	  eGFR.	  However,	  in	  individual	  patients,	  substantial	  increases	  or	  
decreases	  in	  follow-­‐up	  eGFR	  were	  seen	  across	  most	  of	  the	  range	  of	  discharge	  eGFR	  
(Fig	  2).	  	  It	  is	  therefore	  difficult	  to	  predict	  who	  requires	  follow-­‐up	  at	  hospital	  discharge	  
and	  specifically	  a	  higher	  eGFR	  at	  discharge	  should	  not	  be	  taken	  as	  universally	  
reassuring.	  	  	  
	  
Strengths	  and	  limitations	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This	  study	  represents	  a	  comprehensive	  description	  of	  the	  follow-­‐up	  of	  severe	  
AKI	  complicating	  critical	  illness	  in	  a	  populous	  geographical	  area.	  As	  all	  acute	  health	  
care	  in	  our	  region	  is	  provided	  by	  the	  National	  Health	  Service	  hospitals	  we	  can	  be	  
confident	  of	  capturing	  almost	  all	  acute	  RRT	  episodes.	  	  
As	  a	  retrospective	  analysis	  this	  study	  has	  limitations.	  Follow-­‐up	  data	  is	  
incomplete,	  however,	  the	  paucity	  of	  follow-­‐up	  is	  an	  important	  finding	  in	  its	  own	  
right.	  Rates	  of	  pre-­‐morbid	  CKD	  and	  creatinine	  levels	  at	  ICU	  discharge	  were	  lower	  in	  
the	  group	  who	  had	  no	  follow-­‐up,	  however	  approximately	  half	  these	  patients	  still	  had	  
an	  eGFR	  of<60	  at	  hospital	  discharge,	  suggesting	  significant	  potential	  for	  CKD	  in	  these	  
patients.	  	  
However,	  it	  is	  likely	  that	  estimates	  of	  creatinine	  generation	  implicit	  in	  eGFR	  
equations	  are	  poorly	  calibrated	  to	  critically	  ill	  AKI	  patients,	  who	  experience	  
significantly	  decrease	  creatinine	  generation	  [10,11]	  not	  only	  during	  their	  illness	  but	  
also	  at	  the	  time	  of	  hospital	  discharge	  and	  then	  weeks	  into	  their	  recovery;	  eGFR	  could	  
therefore	  significantly	  over-­‐estimate	  true	  GFR	  in	  many	  survivors	  of	  critical	  illness	  for	  
a	  significant	  period	  after	  the	  acute	  illness.[5]	  Use	  of	  CKD-­‐EPI	  eGFR	  in	  this	  study	  is	  
pragmatic,	  it	  is	  a	  simple	  clinical	  tool	  by	  clinician	  to	  assess	  AKI	  recovery	  and,	  in	  the	  
absence	  of	  measured	  GFR,	  gives	  a	  lower	  limit	  for	  the	  prevalence	  of	  CKD.	  It	  is	  thus	  
likely	  that	  the	  prevalence	  of	  true	  GFR	  below	  60	  or	  30	  in	  our	  population	  is	  higher	  than	  
that	  indicated	  by	  eGFR,	  particularly	  at	  hospital	  discharge;	  however	  this	  would	  only	  
strengthen	  our	  findings	  and	  recommendations.	  
Finally	  patterns	  of	  AKI	  follow-­‐up	  we	  have	  observed	  may	  be	  specific	  to	  
environments	  like	  the	  UK,	  many	  European	  Nations	  and	  Australia	  where	  CRRT	  is	  
prescribed	  and	  provided	  by	  the	  ICU	  clinical	  team.	  	  In	  this	  setting	  nephrology	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consultation	  is	  usually	  only	  undertaken	  if	  there	  are	  specific	  indications,	  or	  need	  for	  
ongoing	  RRT	  following	  recovery	  from	  critical	  illness.	  	  This	  practice	  pattern	  has	  the	  
advantage	  of	  rapid	  24h	  access	  to	  RRT	  in	  the	  critically	  ill	  and	  integration	  of	  CRRT	  into	  
integrated	  multi-­‐organ	  support	  overseen	  by	  an	  intensivist,	  however	  it	  does	  require	  
specific	  referral	  for	  long-­‐term	  follow-­‐up.	  We	  did	  not	  study	  patients	  outside	  the	  ICU	  
who	  received	  intermittent	  haemodialysis	  (IHD)	  for	  AKI	  as	  a	  single	  organ	  failure	  in	  
renal	  units,	  where	  follow	  up	  may	  be	  more	  comprehensive.	  All	  RRT	  provided	  in	  the	  in	  
ICU	  this	  study	  was	  CRRT,	  however	  as	  recent	  evidence	  suggests	  that	  renal	  outcomes	  
are	  if	  anything	  worse	  with	  first	  use	  of	  IHD	  for	  AKI	  in	  the	  ICU	  [12]	  our	  findings	  
regarding	  development	  and	  progression	  of	  CKD	  would	  be	  expected	  to	  be	  more	  
significant	  in	  setting	  where	  IHD	  is	  used	  in	  the	  ICU.	  
In	  support	  of	  our	  findings,	  a	  large	  retrospective	  analysis	  of	  US	  Veterans	  
Administration	  Hospitals	  patients	  found	  that	  only	  a	  minority	  of	  nearly	  4000	  AKI-­‐
survivors	  were	  referred	  for	  nephrology	  follow-­‐up,	  despite	  the	  a	  likely	  higher	  level	  of	  
specialist	  nephrology	  consultation	  in	  the	  ICU	  in	  a	  US	  healthcare	  environment.[13]	  
The	  study	  analysed	  persistent	  renal	  dysfunction	  30	  days	  after	  the	  peak	  AKI	  and	  
found	  despite	  a	  60%	  prevalence	  of	  CKD	  prior	  to	  the	  renal	  injury,	  only	  8.5%	  (10.6%	  of	  
AKI	  III	  survivors)	  were	  referred	  to	  a	  nephrologist	  for	  follow	  up.	  
	  
Implications	  and	  future	  research	  
	   It	   is	  now	  well	  established	  that	  AKI	   is	  major	  risk	  factors	  for	  the	  development	  
and	   progression	   of	   CKD	   [14-­‐16],	   even	   with	   apparent	   recovery	   to	   baseline	  
function.[17,18]	  Furthermore	  CKD	  after	  AKI	  has	  been	  associated	  with	  increased	  risk	  
of	  death	  and	  cardiovascular	  morbidity.[19,20]	  	  




	   Evidence	   exists	   from	   a	   Canadian	   Study	   that	   contact	   with	   a	   renal	   physician	  
after	   severe	   AKI	   (as	   opposed	   to	   with	   a	   cardiologist	   or	   general	   practitioner)	   may	  
improve	   outcomes	   in	   patients	   that	   are	   not	   already	   known	   to	   a	   Renal	   service.[21]	  
Targeted	   follow-­‐up	   and	   simple	   medical	   interventions	   recommended	   for	   patients	  
with	  CKD	  could	  modify	   long-­‐term	  outcomes.	  A	   recent	  UK	  health	  economic	  analysis	  
has	   suggested	   that	  post-­‐discharge	   healthcare	   costs	   attributable	   to	   inpatient-­‐AKI	   in	  
2010–11	  would	   be	   £179	  million,	   primarily	   due	   to	   increased	   incidence	   of	   CKD	   and	  
need	   for	   RRT.[22]	   It	   has	   been	   estimated	   that	   prescription	   of	  ACE-­‐inhibitors	   or	  
Angiotensin	  Receptor	  Blockers	   to	  patients	  with	  CKD	  could	  save	  £470	  per	  patient	  in	  
UK	   healthcare	   costs	   over	   5yrs	   by	   prevention	   of	   cardiovascular	   and	   other	  
complications	  of	  CKD	  progression.[23]	  	  
	   Despite	  this	  potential	  financial	  gain,	  and	  evidence	  of	  poor	  follow	  up	  rates	  in	  
two	   other	   similar	   health	   economies,	   we	   have	   found	   very	   low	   rates	   of	   systematic	  
renal	  follow-­‐up	  after	  RRT-­‐requiring	  AKI	  in	  the	  ICU,	  and	  that	  it	  is	  difficult	  to	  predict,	  at	  
the	   time	   of	   hospital	   discharge,	   whether	   renal	   function	  will	   subsequently	   improve,	  
stabilize	   or	   worsen.	   In	   light	   of	   our	   findings,	   we	   suggest	   an	   algorithm	   (Fig.	   4)	   as	   a	  
guideline	  for	  follow	  up	  for	  patients	  surviving	  severe	  AKI.	  While,	  as	  we’ve	  discussed,	  
use	   of	   eGFR,	   has	   significant	   drawbacks,	   it	   is	   the	   existing	   methodology	   used	   to	  
compare	  renal	  function	  at	  discharge	  and	  during	  follow-­‐up,	  potentially	  supplemented	  
by	  more	   formal	   assessment	   of	   true	   GFR	   in	   selected	   patients.	   This	   pathway	  would	  
provide	  a	  platform	  to	  study	  the	  true	  epidemiology	  of	  CKD	  after	  AKI	  and	  the	  effects	  of	  
intervention	   on	   long-­‐term	   health	   and	   healthcare	   costs.	   Follow-­‐up	   would	   place	   an	  
additional	  burden	  on	  renal	  services	  of	  ~190	  patients/year	  in	  our	  region	  for	  patients	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requiring	   RRT,	   but	   potentially	   greater	   if	   this	   pathway	   was	   applied	   to	   patients	  
experiencing	   less	   severe	   AKI.	   Thus	   we	   emphasize	   the	   early	   recognition	   and	  
treatment	   of	   CKD	   after	   AKI,	   which	   if	   stable	   can	   be	   subsequently	   monitored	   and	  
managed	  in	  primary	  care.	  
	  
Conclusions	  
After	  critical	  illness	  complicated	  by	  severe	  AKI,	  it	  is	  difficult	  predict	  in	  which	  
patients	  renal	  function	  will	  improve,	  stabilize	  or	  worsen.	  Despite	  severe-­‐AKI,	  only	  
36%	  of	  patients	  who	  could	  have	  potentially	  undergone	  reassessment	  of	  renal	  
function	  after	  3	  months	  did	  so,	  and	  only	  12%	  received	  specialist	  renal	  follow-­‐up.	  	  In	  
those	  whose	  renal	  function	  was	  reassessed,	  prevalence	  of	  CKD	  was	  significantly	  
increased.	  There	  is	  thus	  a	  strong	  justification	  for	  a	  specialist	  follow-­‐up	  pathway	  for	  
patients	  experiencing	  significant	  AKI	  complicating	  critical	  illness.	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Table	  1:	  Baseline	  demographics	  of	  all	  261	  patients	  with	  AKI	  requiring	  RRT	  who	  were	  
not	  previously	  known	  to	  nephrology	  services.	  CKD	  is	  defined	  by	  eGFR<60	  by	  the	  CKD-­‐
EPI	  equation.	  Medians	  with	  ranges	  presented.	  Between	  group	  comparisons	  by	  
Mann-­‐Whitney	  U	  test	  of	  Fisher’s	  Exact	  Test	  as	  appropriate.	  
	  
	   Patients	  with	  AKI	  
requiring	  RRT	  who	  




Patients	  with	  AKI	  
requiring	  RRT	  but	  





Number	   124	   137	   	  
Age	  (Range)	   66	  (21	  –	  88)	   64	  (18	  –	  90)	   NS	  
Male	  (%)	   78	  (69)	   82	  (60)	   NS	  
Ethnicity	  (%)	  
	   White	  British	  
	   White	  Other	  
	   Black	  
	   South	  Asian	  



















Reason	  for	  Admission	  (%)	  
	   Medical	  
	   Emergency	  Surgery	  
	   Elective	  Surgery	  
















Baseline	  Renal	  Function	  
	   N	  available	  (%)	  
	   N	  of	  those	  with	  CKD	  (%)	  
	   Creatinine	  (mmol/L)	  




99	  (51	  –	  398)	  




91	  (43	  –	  546)	  






Discharge	  Renal	  Function	  
	   Creatinine	  (mmol/L)	  
	  	  	  	  eGFR	  (ml/min/1.73m2)	  
	  
121(27-­‐617)	  
47	  (5-­‐	  >90)	  
	  
94	  (33-­‐806)	  




Presumed	  Cause	  of	  AKI	  (%)	  
	   Autoimmune	   	  
	   Cardiogenic	  
	   Contrast	  induced	  
	   Hemodynamic	  
	   Ischaemic	  
	   Metabolic	  
	   Obstruction	  
	   Rhabdomyolysis	  
	   Sepsis	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Table	  2.	  CKD	  categories	  before	  and	  after	  AKI	  requiring	  renal	  replacement	  therapy	  in	  
the	  104	  patients	  with	  baseline,	  hospital	  discharge	  and	  follow	  up	  creatinine	  
measurements.	  Comparisons	  by	  McNemar’s	  test	  for	  proportion	  of	  patients	  in	  stated	  
AKI	  category	  or	  greater	  (note	  formally	  CKD	  status	  cannot	  be	  diagnosed	  until	  renal	  




Baseline	   Hospital	  discharge	   3	  –	  6	  month	  follow	  up	  
N	   N	  	  
p	  vs.	  baseline	  
(for	  CKD	  stage	  
or	  greater)	  
N	  	  
p	  vs.	  baseline	  
(for	  CKD	  stage	  
or	  greater)	  
p	  vs.	  discharge	  
(for	  CKD	  stage	  
or	  greater)	  
0,	  I,	  II	   51	  (49%)	  	   30	  (29%)	   -­‐	   31	  (30%)	   -­‐	   NS	  
IIIa	   24	  (23%)	   23	  (22%)	   <0.001	   25	  (24%)	   <0.001	   NS	  
IIIb	   22	  (21%)	   29	  (28%)	   <0.001	   32	  (31%)	   <0.001	   NS	  
IV	   4	  (4%)	   17	  (16%)	   <0.001	   10	  (10%)	   0.008	   NS	  






















Figure	  1:	  Flow	  chart	  of	  patient	  analysis	  	  




5544	  patients	  admitted	  to	  
intensive	  care 
394	  received	  RRT	  and	  survived	  
to	  hospital	  discharge 
781	  Received	  RRT 
219	  available	  for	  follow-­‐up 
7	  were	  discharged	  on	  RRT 
261	  received	  RRT	  for	  AKI	  who	  
were	  not	  previously	  known	  to	  
the	  renal	  services 
22	  Died	  within	  three	  months	  of	  
discharge 
8	  were	  re-­‐admitted	  to	  hospital	  within	  
three	  months	  of	  discharge 
124	  Had	  a	  creatinine	  
measurement	  3-­‐6	  months	  
post	  discharge 
5	  transferred	  out	  of	  area	  to	  continue	  
their	  rehabilitation	  and	  their	  
outcomes	  are	  unknown 
104	  Had	  a	  creatinine	  measurement	  
at	  baseline	  and	  3-­‐6	  months	  post	  
discharge 
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Figure	  2:	  Relationship	  between	  eGFR	  at	  discharge	  and	  at	  3-­‐6	  month	  follow-­‐up	  after	  
RRT-­‐requiring	  AKI	  in	  124	  patients.	  Higher	  eGFRs	  at	  discharge	  tended	  to	  decline	  at	  
follow-­‐up	  while	  lower	  eGFRs	  tended	  to	  increase,	  but	  the	  extent	  was	  highly	  variable	  
between	  patients.	  Linear	  regression	  (LR)	  line	  is	  shown	  with	  95%	  confidence	  interval	  
(CI).	  Regression	  equation:	  Follow-­‐up	  =	  0.68	  x	  Baseline	  +	  16	  ,	  r2=0.59.	  Line	  of	  identity	  
and	  predicted	  regression	  to	  the	  mean	  (RTM)	  effect	  with	  repeated	  observations	  are	  
also	  shown,	  changes	  in	  eGFR	  above	  and	  below	  the	  mean	  are	  larger	  than	  that	  
effected	  from	  RTM	  alone.	  
	  























Figure	  3:	  Relationship	  between	  eGFR	  at	  baseline	  and	  at	  3-­‐6	  month	  follow-­‐up	  after	  
RRT-­‐requiring	  AKI	  in	  104	  patients.	  Overall,	  there	  was	  a	  consistent	  trend	  to	  reduction	  
in	  eGFR	  at	  follow-­‐up,	  but	  the	  extent	  was	  highly	  variable	  between	  patients.	  Linear	  
regression	  (LR)	  line	  is	  shown	  with	  95%	  confidence	  interval	  (CI).	  Regression	  equation:	  
Follow-­‐up	  =	  0.81	  x	  Baseline	  +	  1	  ,	  r2=0.63.	  Line	  of	  identity	  and	  predicted	  regression	  to	  
the	  mean	  (RTM)	  effect	  with	  repeated	  observations	  are	  also	  shown.	  
	  



















Nephron	  2015;129:164-­‐70	   	   	   	   	   	  DOI:	  10.1159/000371448	  	  
 
 21 
Figure	  4:	  A	  proposed	  pathway	  for	  follow	  up	  of	  patients	  who	  survive	  an	  episode	  of	  





*	  Adverse	  features	  suggesting	  need	  for	  early	  follow-­‐up	  include	  a	  significant	  increase	  
in	  serum	  creatinine	  from	  pre-­‐morbid	  baseline	  to	  discharge	  (new	  overt	  CKD	  or	  
unrecovered	  AKI)	  or	  the	  presence	  of	  significant	  renal	  impairment	  (suggested	  as	  a	  
serum	  creatinine	  of	  >175µmol/L	  (2mg/dl)	  or	  eGFR	  <30ml/min/1.73m2).	  Consider	  
formal	  measurement	  of	  GFR	  or	  Creatinine	  Clearance	  in	  patients	  with	  prolonged	  
critical	  illness	  or	  significant	  loss	  of	  muscle	  mass.	  
	  
†	  Patients	  with	  specific	  features	  including	  persistent	  haematuria	  or	  proteinuria	  (Urine	  
Protein:Creatinine	  Ratio	  >100	  mg/mmol),	  proven	  or	  suspected	  glomerulonephritis,	  
refractory	  hypertension,	  familial	  renal	  disease,	  recurrent	  or	  extensive	  nephrolithiasis,	  
or	  likely	  progression	  to	  ESRD	  within	  1	  year	  should	  be	  referred	  directly	  to	  the	  
appropriate	  specialist	  nephrology	  clinic.	  
